OpenAI's GPT‑Rosalind
- OpenAI released GPT‑Rosalind, a domain‑specific model focused on life‑sciences tasks like biochemistry and genomics. - Access is gated through a 'trusted‑access' programme with launch partners including Amgen, Moderna and Thermo Fisher Scientific. - OpenAI reported a 0.751 pass rate on BixBench and says GPT‑Rosalind outperformed GPT‑5 on that benchmark. (onhealthcare.tech)
OpenAI has released GPT‑Rosalind, a biology-focused artificial intelligence model that it is limiting to vetted research customers in a trusted-access preview. (openai.com) The company announced GPT‑Rosalind on April 16, 2026, and said the model is built for biology, drug discovery, and translational medicine rather than general-purpose chat. OpenAI said it is available in ChatGPT, Codex, and the application programming interface for qualified customers. (openai.com) In plain terms, the model is meant to help scientists work through the early steps of research: reading papers, checking databases, comparing gene and protein data, and planning experiments. OpenAI said those early discovery steps feed into a drug-development process that often takes 10 to 15 years in the United States. (openai.com) OpenAI is rolling it out through a restricted program rather than a broad product launch. Its help center says GPT‑Rosalind is currently available only to eligible U.S. enterprise customers with biology research use cases, and not to individual researchers or customer-facing products. (help.openai.com) That gate reflects the kind of work the model is supposed to do. OpenAI’s life-science special-access policy says vetted customers may get a less restricted version of its systems for beneficial research, while the company says it will still block outputs tied to weaponization or other acute risks. (help.openai.com) OpenAI said it is already working with Amgen, Moderna, the Allen Institute, and Thermo Fisher Scientific. It also launched a Life Sciences research plugin for Codex that connects models to more than 50 scientific tools and data sources. (openai.com) The company is pitching GPT‑Rosalind as part of a broader move into pharmaceutical and biotech research. Fierce Biotech reported on April 17 that OpenAI had recently announced a separate partnership with Novo Nordisk, while Eli Lilly had already worked with OpenAI on drug discovery in 2024. (fiercebiotech.com) OpenAI also said GPT‑Rosalind beat GPT‑5 on BixBench, a benchmark for bioinformatics and data-analysis tasks, with a reported pass rate of 0.751. That claim comes from OpenAI’s own evaluation materials, and the company has not opened the model for general public testing. (openai.com) The immediate result is a narrower kind of AI launch: less a consumer product than a controlled lab tool. For now, OpenAI is putting GPT‑Rosalind in the hands of a small set of enterprise biology teams and asking the rest of the market to wait. (openai.com)
